Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Warmly greet Discretion and Thoughtfulness - 2Study reveals how fast weight returns after ending GLP-1 drugs
- 3State asks High Court to reject challenge to anti-UNRWA laws ahead of Monday hearing
- 4Vote In favor of Your Favored Cereal
- 5Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
- Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- Volkswagen Plant Could Pivot From Building Cars to Supporting Iron Dome Systems
- IDF destroys Hamas shaft in northern Gaza with loaded 'ready to fire' rocket aimed at Sderot
- The Manual for Electric Vehicles that will be hot merchants in 2023
- 6 Novice Cameras for 2024: Ideal for New Picture takers
- Cannabis reclassification could 'open the floodgates' for research, scientists say
- Hitting the brakes: Hubble Space Telescope watches doomed comet reverse its spin
- Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
